D
David Fitchett
Researcher at University of Toronto
Publications - 194
Citations - 16760
David Fitchett is an academic researcher from University of Toronto. The author has contributed to research in topics: Empagliflozin & Myocardial infarction. The author has an hindex of 40, co-authored 191 publications receiving 13320 citations. Previous affiliations of David Fitchett include Boehringer Ingelheim & St. Michael's GAA, Sligo.
Papers
More filters
Journal ArticleDOI
Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes.
Bernard Zinman,Christoph Wanner,John M. Lachin,David Fitchett,Erich Bluhmki,Stefan Hantel,Michaela Mattheus,Theresa Devins,Odd Erik Johansen,Hans-Juergen Woerle,Uli C. Broedl,Silvio E. Inzucchi +11 more
TL;DR: Patients with type 2 diabetes at high risk for cardiovascular events who received empagliflozin, as compared with placebo, had a lower rate of the primary composite cardiovascular outcome and of death from any cause when the study drug was added to standard care.
Journal ArticleDOI
Sodium Glucose Cotransporter 2 Inhibitors in the Treatment of Diabetes Mellitus: Cardiovascular and Kidney Effects, Potential Mechanisms, and Clinical Applications
TL;DR: Some diabetes clinical practice guidelines now recommend that SGLT2 inhibitors with proven cardiovascular benefit be prioritized in patients with type 2 diabetes mellitus who have not achieved glycemic targets and who have prevalent atherosclerotic cardiovascular disease.
Journal ArticleDOI
Heart failure outcomes with empagliflozin in patients with type 2 diabetes at high cardiovascular risk: results of the EMPA-REG OUTCOME® trial
David Fitchett,Bernard Zinman,Bernard Zinman,Christoph Wanner,John M. Lachin,Stefan Hantel,Afshin Salsali,Odd Erik Johansen,Hans-Juergen Woerle,Uli C. Broedl,Silvio E. Inzucchi +10 more
TL;DR: In patients with type 2 diabetes and high cardiovascular risk, empagliflozin reduced heart failure hospitalization and cardiovascular death, with a consistent benefit in patients with and without baseline heart failure.
Journal ArticleDOI
How Does Empagliflozin Reduce Cardiovascular Mortality? Insights From a Mediation Analysis of the EMPA-REG OUTCOME Trial
Silvio E. Inzucchi,Bernard Zinman,David Fitchett,Christoph Wanner,Ele Ferrannini,Martin Schumacher,Claudia Schmoor,Kristin Ohneberg,Odd Erik Johansen,Jyothis T. George,Stefan Hantel,Erich Bluhmki,John M. Lachin +12 more
TL;DR: In this exploratory analysis from the EMPA-REG OUTCOME trial, changes in markers of plasma volume were the most important mediators of the reduction in risk of CV death with empagliflozin versus placebo.
Journal ArticleDOI
Effect of calcium-based versus non-calcium-based phosphate binders on mortality in patients with chronic kidney disease: an updated systematic review and meta-analysis
Sophie A. Jamal,Sophie A. Jamal,Ben Vandermeer,Paolo Raggi,David C. Mendelssohn,David C. Mendelssohn,Trish Chatterley,Marlene Dorgan,Charmaine E. Lok,David Fitchett,Ross T. Tsuyuki +10 more
TL;DR: Analysis of the 11 randomised trials that reported an outcome of mortality showed that patients assigned to non-calcium-based binders had a 22% reduction in all-cause mortality compared with those assigned to calcium-based phosphate binders.